BIRC5 and metastatic melanoma: This feature makes survivin a target to develop survivin-targeting vaccines to treat malignancies such as melanoma, in a recent phase II study a vaccine using the peptides Sur1M2 and IDO5 was combined with the chemotherapy temozolomide (TMZ) for treatment of metastatic melanoma patients in order to target several immune inhibiting mechanisms and the highly malignant cells expressing survivin.